Skip to Main content Skip to Navigation
Journal articles

[MTOR inhibitors: from transplantation to oncology. AFU 2006 Transplantation Committee Review of the literature]

Abstract : The use of mTOR inhibitors started about 30 years ago following the discovery of rapamycin, a macrolide derived from a soilborne microorganism Streptomyces hygroscopicus that exerts antibiotic, immunosuppressive and antiproliferative properties. Initially intended to be used as an antibiotic, a more detailed understanding of the mechanism of action of this class of drugs has rationalized and validated its use in the field of transplantation and oncology. Many clinical trials on mTOR inhibitors have been conducted in these two fields, in which urologists are actively involved. This review summarizes the current knowledge on the mechanism of action and clinical applications of mTOR inhibitors in renal transplantation and oncology.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00479738
Contributor : Philippe Saas <>
Submitted on : Sunday, May 2, 2010 - 2:25:28 PM
Last modification on : Tuesday, October 27, 2020 - 2:35:49 PM

Identifiers

  • HAL Id : inserm-00479738, version 1
  • PUBMED : 17969790

Collections

Citation

Yann Neuzillet, Georges Karam, Eric Lechevallier, François Kleinclauss. [MTOR inhibitors: from transplantation to oncology. AFU 2006 Transplantation Committee Review of the literature]. Progrès en Urologie, Elsevier Masson, 2007, 17 (5), pp.928-33. ⟨inserm-00479738⟩

Share

Metrics

Record views

101